<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33176455</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1941-3297</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Circulation. Heart failure</Title>
          <ISOAbbreviation>Circ Heart Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.</ArticleTitle>
        <Pagination>
          <StartPage>e007405</StartPage>
          <MedlinePgn>e007405</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCHEARTFAILURE.120.007405</ELocationID>
        <Abstract>
          <AbstractText>Myocarditis is an inflammatory disease of the heart that may occur because of infections, immune system activation, or exposure to drugs. The diagnosis of myocarditis has changed due to the introduction of cardiac magnetic resonance imaging. We present an expert consensus document aimed to summarize the common terminology related to myocarditis meanwhile highlighting some areas of controversies and uncertainties and the unmet clinical needs. In fact, controversies persist regarding mechanisms that determine the transition from the initial trigger to myocardial inflammation and from acute myocardial damage to chronic ventricular dysfunction. It is still uncertain which viruses (besides enteroviruses) cause direct tissue damage, act as triggers for immune-mediated damage, or both. Regarding terminology, myocarditis can be characterized according to etiology, phase, and severity of the disease, predominant symptoms, and pathological findings. Clinically, acute myocarditis (AM) implies a short time elapsed from the onset of symptoms and diagnosis (generally &lt;1 month). In contrast, chronic inflammatory cardiomyopathy indicates myocardial inflammation with established dilated cardiomyopathy or hypokinetic nondilated phenotype, which in the advanced stages evolves into fibrosis without detectable inflammation. Suggested diagnostic and treatment recommendations for AM and chronic inflammatory cardiomyopathy are mainly based on expert opinion given the lack of well-designed contemporary clinical studies in the field. We will provide a shared and practical approach to patient diagnosis and management, underlying differences between the European and US scientific statements on this topic. We explain the role of histology that defines subtypes of myocarditis and its prognostic and therapeutic implications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ammirati</LastName>
            <ForeName>Enrico</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy (E.A., M.F., P.P.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Frigerio</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy (E.A., M.F., P.P.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adler</LastName>
            <ForeName>Eric D</ForeName>
            <Initials>ED</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla (E.D.A., M.B.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Basso</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy (C.B.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Birnie</LastName>
            <ForeName>David H</ForeName>
            <Initials>DH</Initials>
            <AffiliationInfo>
              <Affiliation>University of Ottawa Heart Institute, Ontario, Canada (D.H.B.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brambatti</LastName>
            <ForeName>Michela</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla (E.D.A., M.B.).</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>IONIS Pharmaceuticals, Carlsbad, CA (M.B.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Friedrich</LastName>
            <ForeName>Matthias G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Diagnostic Radiology, McGill University, Montreal, Quebec, Canada (M.G.F.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klingel</LastName>
            <ForeName>Karin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Germany (K.K.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lehtonen</LastName>
            <ForeName>Jukka</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Heart and Lung Center, Helsinki University Hospital, Finland (J.L.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moslehi</LastName>
            <ForeName>Javid J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.J.M.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pedrotti</LastName>
            <ForeName>Patrizia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy (E.A., M.F., P.P.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rimoldi</LastName>
            <ForeName>Ornella E</ForeName>
            <Initials>OE</Initials>
            <AffiliationInfo>
              <Affiliation>IBFM CNR, Segrate, Italy (O.E.R.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schultheiss</LastName>
            <ForeName>Heinz-Peter</ForeName>
            <Initials>HP</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Cardiac Diagnostics and Therapy, Berlin, Germany (H.-P.S.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tschöpe</LastName>
            <ForeName>Carsten</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Health Center for Regenerative Therapies (BCRT), Charité, University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany (C.T.).</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Charité-University Medicine Berlin, Campus Virchow Klinikum, Germany (C.T.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Cooper</LastName>
            <ForeName>Leslie T</ForeName>
            <Initials>LT</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (L.T.C.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Camici</LastName>
            <ForeName>Paolo G</ForeName>
            <Initials>PG</Initials>
            <AffiliationInfo>
              <Affiliation>Vita Salute University and San Raffaele Hospital, Milano, Italy (P.G.C.).</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL141466</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D059040">Video-Audio Media</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Circ Heart Fail</MedlineTA>
        <NlmUniqueID>101479941</NlmUniqueID>
        <ISSNLinking>1941-3289</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002309" MajorTopicYN="N">Cardiology</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">cardiac magnetic resonance imaging</Keyword>
        <Keyword MajorTopicYN="Y">endomyocardial biopsy</Keyword>
        <Keyword MajorTopicYN="Y">inflammatory cardiomyopathy</Keyword>
        <Keyword MajorTopicYN="Y">myocarditis</Keyword>
        <Keyword MajorTopicYN="Y">viruses</Keyword>
      </KeywordList>
      <CoiStatement>Dr Adler is a consultant for Abbott, Abiomed, AstraZeneca, Endotronix, Ionis, Medtronic, and Novartis, is on the board of directors of Genstem Therapeutics, and is a shareholder of Rocket Pharmaceuticals. Dr Brambatti is an employee at Ionis Pharmaceuticals. Dr Moslehi has served on advisory boards for Pfizer, Novartis, Bristol-Myers Squibb, Deciphera, Audentes Pharmaceuticals, Nektar, Takeda, Ipsen, Myokardia, AstraZeneca, GlaxoSmithKline, Intrexon, and Regeneron and has been supported by National Institutes of Health grants R56 HL141466 and R01 HL141466. Dr Tschöpe is a consultant at Cardiotropic Labs, Miami, FL. Dr Camici is a consultant at Servier. The other authors report no conflicts.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>28</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33176455</ArticleId>
        <ArticleId IdType="mid">NIHMS1628599</ArticleId>
        <ArticleId IdType="pmc">PMC7673642</ArticleId>
        <ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.120.007405</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cooper LT., JrMyocarditis.
N Engl J Med. 2009;360:1526–1538. doi: 10.1056/NEJMra0800028</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5814110</ArticleId>
            <ArticleId IdType="pubmed">19357408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, et al. ; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology working group on myocardial and pericardial diseases.
Eur Heart J. 2013;34:2636–48, 2648a. doi: 10.1093/eurheartj/eht210</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23824828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, et al. 
Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies.
Circulation. 1996;93:841–842. doi: 10.1161/01.cir.93.5.841</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8598070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corrado D, Basso C, Thiene G.
Sudden cardiac death in young people with apparently normal heart.
Cardiovasc Res. 2001;50:399–408. doi: 10.1016/s0008-6363(01)00254-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11334844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harmon KG, Drezner JA, Maleszewski JJ, Lopez-Anderson M, Owens D, Prutkin JM, Asif IM, Klossner D, Ackerman MJ.
Pathogeneses of sudden cardiac death in national collegiate athletic association athletes.
Circ Arrhythm Electrophysiol. 2014;7:198–204. doi: 10.1161/CIRCEP.113.001376</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24585715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, et al. 
Incidence, causes, and outcomes of dilated cardiomyopathy in children.
JAMA. 2006;296:1867–1876. doi: 10.1001/jama.296.15.1867</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17047217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aretz HT.
Myocarditis: the Dallas criteria.
Hum Pathol. 1987;18:619–624. doi: 10.1016/s0046-8177(87)80363-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3297992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Veronese G, Cipriani M, Moroni F, Garascia A, Brambatti M, Adler ED, Frigerio M.
Acute and fulminant myocarditis: a pragmatic clinical approach to diagnosis and treatment.
Curr Cardiol Rep. 2018;20:114
doi: 10.1007/s11886-018-1054-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30259175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, Francis GS, Lenihan D, Lewis EF, McNamara DM, et al. ; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association.
Circulation. 2016;134:e579–e646. doi: 10.1161/CIR.0000000000000455</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27832612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013.
Lancet. 2015;386:743–800. doi: 10.1016/S0140-6736(15)60692-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4561509</ArticleId>
            <ArticleId IdType="pubmed">26063472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charpentier S, Beaune S, Joly LM, Khoury A, Duchateau FX, Briot R, Renaud B, Ageron FXIRU Network. Management of chest pain in the French emergency healthcare system: the prospective observational EPIDOULTHO study.
Eur J Emerg Med. 2018;25:404–410. doi: 10.1097/MEJ.0000000000000481</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28723703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF.
Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.
Circulation. 2015;131:861–870. doi: 10.1161/CIRCULATIONAHA.114.011201</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25587100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, Mantovani R, Varrenti M, Pedrotti P, Conca C, et al. ; Registro Lombardo delle Miocarditi. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter lombardy registry.
Circulation. 2018;138:1088–1099. doi: 10.1161/CIRCULATIONAHA.118.035319</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29764898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe A, Todiere G, Lanzillo C, Scatteia A, et al. ; Cardiac Magnetic Resonance Working Group of the Italian Society of Cardiology. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study.
Am Coll Cardiol. 2017;70:1977–1987. doi: 10.1016/j.jacc.2017.08.044</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29025554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younis A, Matetzky S, Mulla W, Masalha E, Afel Y, Chernomordik F, Fardman A, Goitein O, Ben-Zekry S, Peled Y, et al. 
Epidemiology characteristics and outcome of patients with clinically diagnosed acute myocarditis.
Am J Med. 2020;133:492–499. doi: 10.1016/j.amjmed.2019.10.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31712098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White JA, Hansen R, Abdelhaleem A, Mikami Y, Peng M, Rivest S, Satriano A, Dykstra S, Flewitt J, Heydari B, et al. 
Natural history of myocardial injury and chamber remodeling in acute myocarditis.
Circ Cardiovasc Imaging. 2019;12:e008614
doi: 10.1161/CIRCIMAGING.118.008614</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31269814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K, Cuddy S, Aghayev A, Steigner M, Blankstein R, et al. 
Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis.
J Am Coll Cardiol. 2017;70:1964–1976. doi: 10.1016/j.jacc.2017.08.050</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506846</ArticleId>
            <ArticleId IdType="pubmed">29025553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanguineti F, Garot P, Mana M, O’h-Ici D, Hovasse T, Unterseeh T, Louvard Y, Troussier X, Morice MC, Garot J.
Cardiovascular magnetic resonance predictors of clinical outcome in patients with suspected acute myocarditis.
J Cardiovasc Magn Reson. 2015;17:78
doi: 10.1186/s12968-015-0185-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4553007</ArticleId>
            <ArticleId IdType="pubmed">26318624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, et al. 
Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery.
J Am Coll Cardiol. 2012;59:1604–1615. doi: 10.1016/j.jacc.2012.01.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22365425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, Salvi A, Perkan A, Di Lenarda A, Bussani R, et al. 
Long-term evolution and prognostic stratification of biopsy-proven active myocarditis.
Circulation. 2013;128:2384–2394. doi: 10.1161/CIRCULATIONAHA.113.003092</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24084750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB.
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
Lancet. 2018;391:933
doi: 10.1016/S0140-6736(18)30533-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6668330</ArticleId>
            <ArticleId IdType="pubmed">29536852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose NR.
Learning from myocarditis: mimicry, chaos and black holes.
F1000Prime Rep. 2014;6:25
doi: 10.12703/P6-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4018180</ArticleId>
            <ArticleId IdType="pubmed">24904749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trachtenberg BH, Hare JM.
Inflammatory cardiomyopathic syndromes.
Circ Res. 2017;121:803–818. doi: 10.1161/CIRCRESAHA.117.310221</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28912184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fung G, Luo H, Qiu Y, Yang D, McManus B.
Myocarditis.
Circ Res. 2016;118:496–514. doi: 10.1161/CIRCRESAHA.115.306573</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26846643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veronese G, Ammirati E, Brambatti M, Merlo M, Cipriani M, Potena L, Sormani P, Aoki T, Sugimura K, Sawamura A, et al. 
Viral genome search in myocardium of patients with fulminant myocarditis.
Eur J Heart Fail. 2020;22:1277–1280. doi: 10.1002/ejhf.1738</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31926056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, Sanchez-Munoz JJ, Oliva-Sandoval MJ, Gimeno JR.
Genetics of myocarditis in arrhythmogenic right ventricular dysplasia.
Heart Rhythm. 2015;12:766–773. doi: 10.1016/j.hrthm.2015.01.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25616123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belkaya S, Kontorovich AR, Byun M, Mulero-Navarro S, Bajolle F, Cobat A, Josowitz R, Itan Y, Quint R, Lorenzo L, et al. 
Autosomal recessive cardiomyopathy presenting as acute myocarditis.
J Am Coll Cardiol. 2017;69:1653–1665. doi: 10.1016/j.jacc.2017.01.043</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5551973</ArticleId>
            <ArticleId IdType="pubmed">28359509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grogan M, Redfield MM, Bailey KR, Reeder GS, Gersh BJ, Edwards WD, Rodeheffer RJ.
Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy.
J Am Coll Cardiol. 1995;26:80–84. doi: 10.1016/0735-1097(95)00148-s</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7797779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE.
A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.
N Engl J Med. 1995;333:269–275. doi: 10.1056/NEJM199508033330501</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7596370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy RE, 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL.
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.
N Engl J Med. 2000;342:690–695. doi: 10.1056/NEJM200003093421003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10706898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnani JW, Danik HJ, Dec GW, Jr, DiSalvo TG.
Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors.
Am Heart J. 2006;151:463–470. doi: 10.1016/j.ahj.2005.03.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16442915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan E, Iliceto S, Thiene G, et al. 
A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis.
Eur Heart J. 2007;28:1326–1333. doi: 10.1093/eurheartj/ehm076</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17493945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, Lindinger A, Böhm M.
Predictors of outcome in patients with suspected myocarditis.
Circulation. 2008;118:639–648. doi: 10.1161/CIRCULATIONAHA.108.769489</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18645053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inaba O, Satoh Y, Isobe M, Yamamoto T, Nagao K, Takayama M.
Factors and values at admission that predict a fulminant course of acute myocarditis: data from Tokyo CCU Network database.
Heart Vessels. 2017;32:952–959. doi: 10.1007/s00380-017-0960-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28255801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, Petrella D, Garascia A, Pedrotti P, Roghi A, et al. 
Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis.
Circulation. 2017;136:529–545. doi: 10.1161/CIRCULATIONAHA.117.026386</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28576783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imazio M, Angelico G, Andriani M, Lobetti-Bodoni L, Davini O, Giustetto C, Rinaldi M.
Prevalence and prognostic impact of septal late gadolinium enhancement in acute myocarditis with or without preserved left ventricular function.
Am J Cardiol. 2018;122:1955–1958. doi: 10.1016/j.amjcard.2018.08.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30266253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg J, Lovrinovic M, Baltensperger N, Kissel CK, Kottwitz J, Manka R, Patriki D, Scherff F, Schmied C, Landmesser U, et al. 
Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical follow-up.
Open Heart. 2019;6:e000990
doi: 10.1136/openhrt-2018-000990</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6519432</ArticleId>
            <ArticleId IdType="pubmed">31168382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, Sormani P, Aoki T, Sugimura K, Sawamura A, et al. 
Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction.
J Am Coll Cardiol. 2019;74:299–311. doi: 10.1016/j.jacc.2019.04.063</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31319912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E.
Eosinophilic myocarditis: characteristics, treatment, and outcomes.
J Am Coll Cardiol. 2017;70:2363–2375. doi: 10.1016/j.jacc.2017.09.023</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29096807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, et al. 
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Lancet Oncol. 2018;19:1579–1589. doi: 10.1016/S1470-2045(18)30608-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6287923</ArticleId>
            <ArticleId IdType="pubmed">30442497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilotra NA, Minkove N, Bennett MK, Tedford RJ, Steenbergen C, Judge DP, Halushka MK, Russell SD.
Lack of relationship between serum cardiac troponin i level and giant cell myocarditis diagnosis and outcomes.
J Card Fail. 2016;22:583–585. doi: 10.1016/j.cardfail.2015.12.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26768222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bratincsák A, El-Said HG, Bradley JS, Shayan K, Grossfeld PD, Cannavino CR.
Fulminant myocarditis associated with pandemic H1N1 influenza a virus in children.
J Am Coll Cardiol. 2010;55:928–929. doi: 10.1016/j.jacc.2010.01.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20153131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, et al. 
Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19).
JAMA Cardiol. 2020;5:1–6. doi: 10.1001/jamacardio.2020.1096</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7364333</ArticleId>
            <ArticleId IdType="pubmed">32219357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, et al. 
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.
J Am Coll Cardiol. 2018;72:3158–3176. doi: 10.1016/j.jacc.2018.09.072</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30545455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, et al. ; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC white paper.
J Am Coll Cardiol. 2009;53:1475–1487. doi: 10.1016/j.jacc.2009.02.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2743893</ArticleId>
            <ArticleId IdType="pubmed">19389557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatia S, Anstine C, Jaffe AS, Gersh BJ, Chandrasekaran K, Foley TA, Hodge D, Anavekar NS.
Cardiac magnetic resonance in patients with elevated troponin and normal coronary angiography.
Heart. 2019;105:1231–1236. doi: 10.1136/heartjnl-2018-314631</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30948519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luetkens JA, Homsi R, Dabir D, Kuetting DL, Marx C, Doerner J, Schlesinger-Irsch U, Andrie R, Sprinkart AM, Schmeel FC, et al. 
Comprehensive cardiac magnetic resonance for short-term follow-up in acute myocarditis.
J American Heart Assoc. 2016;5:e003603</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5015395</ArticleId>
            <ArticleId IdType="pubmed">27436306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan JA, Lee YJ, Salerno M.
Diagnostic performance of extracellular volume, native T1, and T2 mapping versus lake louise criteria by cardiac magnetic resonance for detection of acute myocarditis: a meta-analysis.
Circ Cardiovasc Imaging. 2018;11:e007598
doi: 10.1161/CIRCIMAGING.118.007598</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6192699</ArticleId>
            <ArticleId IdType="pubmed">30012826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luetkens JA, Faron A, Isaak A, Dabir D, Kuetting D, Feisst A, Schmeel FC, Sprinkart AM, Thomas D.
Comparison of original and 2018 lake louise criteria for diagnosis of acute myocarditis: results of a validation cohort.
Radiology: Cardiothoracic Imaging. 2019;1:e190010</Citation>
        </Reference>
        <Reference>
          <Citation>Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, Fuernau G, de Waha S, Sareban M, Luecke C, et al. 
Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis.
JACC Cardiovasc Imaging. 2012;5:513–524. doi: 10.1016/j.jcmg.2011.11.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22595159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blissett S, Chocron Y, Kovacina B, Afilalo J.
Diagnostic and prognostic value of cardiac magnetic resonance in acute myocarditis: a systematic review and meta-analysis.
Int J Cardiovasc Imaging. 2019;35:2221–2229. doi: 10.1007/s10554-019-01674-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31388815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aquaro GD, Ghebru Habtemicael Y, Camastra G, Monti L, Dellegrottaglie S, Moro C, Lanzillo C, Scatteia A, Di Roma M, Pontone G, et al. ; “Cardiac Magnetic Resonance” Working Group of the Italian Society of Cardiology. Prognostic value of repeating cardiac magnetic resonance in patients with acute myocarditis.
J Am Coll Cardiol. 2019;74:2439–2448. doi: 10.1016/j.jacc.2019.08.1061</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31727281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Moroni F, Sormani P, Peritore A, Milazzo A, Quattrocchi G, Cipriani M, Oliva F, Giannattasio C, Frigerio M, et al. 
Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis.
Int J Cardiol. 2017;231:216–221. doi: 10.1016/j.ijcard.2016.11.282</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27913009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, et al. ; American Heart Association; American College of Cardiology; European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.
Circulation. 2007;116:2216–2233. doi: 10.1161/CIRCULATIONAHA.107.186093</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17959655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny OAmerican Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and initial management of fulminant myocarditis: a scientific statement From the American Heart Association.
Circulation. 2020;141:e69–e92. doi: 10.1161/CIR0000000000000745</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31902242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perel-Winkler A, Bokhari S, Perez-Recio T, Zartoshti A, Askanase A, Geraldino-Pardilla L.
Myocarditis in systemic lupus erythematosus diagnosed by 18F-fluorodeoxyglucose positron emission tomography.
Lupus Sci Med. 2018;5:e000265
doi: 10.1136/lupus-2018-000265</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6069920</ArticleId>
            <ArticleId IdType="pubmed">30094040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birnie DH, Nery PB, Ha AC, Beanlands RS.
Cardiac sarcoidosis.
J Am Coll Cardiol. 2016;68:411–421. doi: 10.1016/j.jacc.2016.03.605</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27443438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, Birnie DH, Chen ES, Cooper LT, Tung RH, et al. 
Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.
J Nucl Cardiol. 2017;24:1741–1758. doi: 10.1007/s12350-017-0978-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28770463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett MK, Gilotra NA, Harrington C, Rao S, Dunn JM, Freitag TB, Halushka MK, Russell SD.
Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009.
Circ Heart Fail. 2013;6:676–684. doi: 10.1161/CIRCHEARTFAILURE.112.000087</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23733916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh V, Mendirichaga R, Savani GT, Rodriguez A, Blumer V, Elmariah S, Inglessis-Azuaje I, Palacios I.
Comparison of utilization trends, indications, and complications of endomyocardial biopsy in native versus donor hearts (from the nationwide inpatient sample 2002 to 2014).
Am J Cardiol. 2018;121:356–363. doi: 10.1016/j.amjcard.2017.10.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29197471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow LH, Radio SJ, Sears TD, McManus BM.
Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis.
J Am Coll Cardiol. 1989;14:915–920. doi: 10.1016/0735-1097(89)90465-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2794278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S.
Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report.
Herz. 2000;25:200–209. doi: 10.1007/s000590050007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10904839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kühl U, Noutsias M, Seeberg B, Schultheiss HP.
Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy.
Heart. 1996;75:295–300. doi: 10.1136/hrt.75.3.295</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC484290</ArticleId>
            <ArticleId IdType="pubmed">8800996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J.
Cardiovascular toxicities associated with immune checkpoint inhibitors.
Cardiovasc Res. 2019;115:854–868. doi: 10.1093/cvr/cvz026</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6452314</ArticleId>
            <ArticleId IdType="pubmed">30715219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorusso R, Centofanti P, Gelsomino S, Barili F, Di Mauro M, Orlando P, Botta L, Milazzo F, Actis Dato G, Casabona R, et al. ; GIROC Investigators. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5-year multi-institutional experience.
Ann Thorac Surg. 2016;101:919–926. doi: 10.1016/j.athoracsur.2015.08.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26518372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakayama T, Sugano Y, Yokokawa T, Nagai T, Matsuyama TA, Ohta-Ogo K, Ikeda Y, Ishibashi-Ueda H, Nakatani T, Ohte N, et al. 
Clinical impact of the presence of macrophages in endomyocardial biopsies of patients with dilated cardiomyopathy.
Eur J Heart Fail. 2017;19:490–498. doi: 10.1002/ejhf.767</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28217949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frustaci A, Russo MA, Chimenti C.
Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study.
Eur Heart J. 2009;30:1995–2002. doi: 10.1093/eurheartj/ehp249</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19556262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klingel K, Selinka HC, Huber M, Sauter M, Leube M, Kandolf R.
Molecular pathology and structural features of enteroviral replication. Toward understanding the pathogenesis of viral heart disease.
Herz. 2000;25:216–220. doi: 10.1007/s000590050009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10904841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, Tahara M, Soga T, Ono Y, Yasukochi S.
Clinical features of acute and fulminant myocarditis in children- 2nd nationwide survey by japanese society of pediatric cardiology and cardiac surgery.
Circ J. 2016;80:2362–2368. doi: 10.1253/circj.CJ-16-0234</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27725476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veronese G, Cipriani M, Bottiroli M, Garascia A, Mondino M, Pedrotti P, Pini D, Cozzi O, Messina A, Droandi G, et al. 
Fulminant myocarditis triggered by OC43 subtype coronavirus: a disease deserving evidence-based care bundles.
J Cardiovasc Med (Hagerstown). 2020;21:529–531. doi: 10.2459/JCM.0000000000000989</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32487867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bock CT, Klingel K, Kandolf R.
Human parvovirus B19-associated myocarditis.
N Engl J Med. 2010;362:1248–1249. doi: 10.1056/NEJMc0911362</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20357294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschöpe C, Elsanhoury A, Schlieker S, Van Linthout S, Kühl U.
Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence.
Eur J Heart Fail. 2019;21:1468–1469. doi: 10.1002/ejhf.1560</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31476088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca HP, Heymans S.
Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature.
Eur J Heart Fail. 2016;18:1430–1441. doi: 10.1002/ejhf.665</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27748022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, Groetzbach G, Pauschinger M, Escher F, Arbustini E, et al. 
Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-β treatment in patients with chronic viral cardiomyopathy.
Clin Res Cardiol. 2016;105:763–773. doi: 10.1007/s00392-016-0986-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27112783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haslam A, Prasad V.
Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs.
JAMA Netw Open. 2019;2:e192535
doi: 10.1001/jamanetworkopen.2019.2535</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6503493</ArticleId>
            <ArticleId IdType="pubmed">31050774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, et al. 
Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology.
Circulation. 2019;140:80–91. doi: 10.1161/CIRCULATIONAHA.118.034497</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6779326</ArticleId>
            <ArticleId IdType="pubmed">31390169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. 
Fulminant myocarditis with combination immune checkpoint blockade.
N Engl J Med. 2016;375:1749–1755. doi: 10.1056/NEJMoa1609214</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5247797</ArticleId>
            <ArticleId IdType="pubmed">27806233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, et al. 
Myocarditis in patients treated with immune checkpoint inhibitors.
J Am Coll Cardiol. 2018;71:1755–1764. doi: 10.1016/j.jacc.2018.02.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6196725</ArticleId>
            <ArticleId IdType="pubmed">29567210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH, Lichtman AH.
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.
Circulation. 2007;116:2062–2071. doi: 10.1161/CIRCULATIONAHA.107.709360</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17938288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morimoto S, Kubo N, Hiramitsu S, Uemura A, Ohtsuki M, Kato S, Kato Y, Sugiura A, Miyagishima K, Mori N, et al. 
Changes in the peripheral eosinophil count in patients with acute eosinophilic myocarditis.
Heart Vessels. 2003;18:193–196. doi: 10.1007/s00380-003-0721-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14520487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Jr, Berry GJ, Shabetai R.
Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter giant cell myocarditis study group investigators.
N Engl J Med. 1997;336:1860–1866. doi: 10.1056/NEJM199706263362603</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9197214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, Bailey KR, Cooper LT.
A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis.
J Am Coll Cardiol. 2003;41:322–329. doi: 10.1016/s0735-1097(02)02715-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12535829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M.
Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression.
Circ Heart Fail. 2013;6:15–22. doi: 10.1161/CIRCHEARTFAILURE.112.969261</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23149495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, Menon S, Mullen GM, Jaski B, Bailey KR, et al. ; Giant Cell Myocarditis Treatment Trial Investigators. Usefulness of immunosuppression for giant cell myocarditis.
Am J Cardiol. 2008;102:1535–1539. doi: 10.1016/j.amjcard.2008.07.041</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2613862</ArticleId>
            <ArticleId IdType="pubmed">19026310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M.
Long-term outcome and its predictors in giant cell myocarditis.
Eur J Heart Fail. 2016;18:1452–1458. doi: 10.1002/ejhf.606</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27407025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, et al. 
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task force on clinical practice guidelines and the heart rhythm society.
Circulation. 2018;138:e272–e391. doi: 10.1161/CIR.0000000000000549</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29084731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elamm CA, Al-Kindi SG, Bianco CM, Dhakal BP, Oliveira GH.
Heart transplantation in giant cell myocarditis: analysis of the united network for organ sharing registry.
J Card Fail. 2017;23:566–569. doi: 10.1016/j.cardfail.2017.04.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28449952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiff C, Missov E.
A Case of fulminant lymphocytic myocarditis responsive to immunosuppression.
Am J Med. 2018;131:e465–e466. doi: 10.1016/j.amjmed.2018.06.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30025879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW.
Gamma-globulin treatment of acute myocarditis in the pediatric population.
Circulation. 1994;89:252–257. doi: 10.1161/01.cir.89.1.252</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8281654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou HW, Wang CH, Lin LY, Chi NH, Chou NK, Yu HY, Chen YS.
Prognostic factors for heart recovery in adult patients with acute fulminant myocarditis and cardiogenic shock supported with extracorporeal membrane oxygenation.
J Crit Care. 2020;57:214–219. doi: 10.1016/j.jcrc.2020.03.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32220770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courand PY, Croisille P, Khouatra C, Cottin V, Kirkorian G, Bonnefoy E.
Churg-strauss syndrome presenting with acute myocarditis and cardiogenic shock.
Heart Lung Circ. 2012;21:178–181. doi: 10.1016/j.hlc.2011.09.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21963398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotlib J, Cools J, Malone JM, 3rd, Schrier SL, Gilliland DG, Coutré SE.
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Blood. 2004;103:2879–2891. doi: 10.1182/blood-2003-06-1824</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15070659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuenzli E, Neumayr A, Chaney M, Blum J.
Toxocariasis-associated cardiac diseases–a systematic review of the literature.
Acta Trop. 2016;154:107–120. doi: 10.1016/j.actatropica.2015.11.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26571071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Oliva F, Belli O, Bonacina E, Pedrotti P, Turazza FM, Roghi A, Paino R, Martinelli L, Frigerio M.
Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days.
J Cardiovasc Med (Hagerstown). 2016;17suppl 2e151–e153. doi: 10.2459/JCM.0000000000000250</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25643196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suarez-Barrientos A, Wong J, Bell A, Lyster H, Karagiannis G, Banner NR.
Usefulness of rabbit anti-thymocyte globulin in patients with giant cell myocarditis.
Am J Cardiol. 2015;116:447–451. doi: 10.1016/j.amjcard.2015.04.040</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26048854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma JI, Ammirati E, Brambatti M, Adler E.
Biventricular intravascular microaxial blood pumps and immunosuppressio as a bridge to recovery in giant cell myocarditis.
J Am Coll Cardiol Case Rep. 2020;2:1484–1488</Citation>
        </Reference>
        <Reference>
          <Citation>Evans JD, Pettit SJ, Goddard M, Lewis C, Parameshwar JK.
Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation.
J Heart Lung Transplant. 2016;35:256–258. doi: 10.1016/j.healun.2015.10.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26508724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y, Espinosa GCatastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab.
Autoimmun Rev. 2013;12:1085–1090. doi: 10.1016/j.autrev.2013.05.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23777822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellanos-Moreira R, Rodríguez-García S, López-Sobrino T, Capdevila A, Prieto-González S, Espinosa G.
Successful extracorporeal membrane oxygenation in a patient with fulminant lupus myocarditis.
Rev Esp Cardiol (Engl Ed). 2017;70:1013–1014. doi: 10.1016/j.rec.2016.12.037</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28131563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A.
Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin.
J Immunother. 2018;41:332–335. doi: 10.1097/CJI.0000000000000239</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29965858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH., JrAlemtuzumab for immune-related myocarditis due to PD-1 therapy.
N Engl J Med. 2019;380:2375–2376. doi: 10.1056/NEJMc1903064</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31189042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M.
Abatacept for severe immune checkpoint inhibitor-associated myocarditis.
N Engl J Med. 2019;380:2377–2379. doi: 10.1056/NEJMc1901677</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31189043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syed FF, Bleeker JS, Glockner J, Pardanani A, Cooper LT., JrResponse to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging.
J Am Coll Cardiol. 2012;59:430
doi: 10.1016/j.jacc.2011.06.078</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22261167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fussner LA, Karlstedt E, Hodge DO, Fine NM, Kalra S, Carmona EM, Utz JP, Isaac DL, Cooper LT.
Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres.
Eur J Heart Fail. 2018;20:1713–1720. doi: 10.1002/ejhf.1319</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30378224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veronese G, Cipriani M, Petrella D, Geniere Nigra S, Pedrotti P, Garascia A, Masciocco G, Bramerio MA, Klingel K, Frigerio M, et al. 
Recurrent cardiac sarcoidosis after heart transplantation.
Clin Res Cardiol. 2019;108:1171–1173. doi: 10.1007/s00392-019-01485-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31073636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, Gula L, Ha A, Healey JS, Inoue Y, et al. 
Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).
Am Heart J. 2020;220:246–252. doi: 10.1016/j.ahj.2019.10.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7367280</ArticleId>
            <ArticleId IdType="pubmed">31911261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper LJ, McCarthy M, Ribeiro Neto ML, Hachamovitch R, Pearson K, Bonanno B, Shaia J, Brunken R, Joyce E, Culver DA.Infliximab for refractory cardiac sarcoidosis.
Am J Cardiol. 2019;124:1630–1635. doi: 10.1016/j.amjcard.2019.07.067</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31500815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandolin R, Lehtonen J, Kupari M.
Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults.
Circ Arrhythm Electrophysiol. 2011;4:303–309. doi: 10.1161/CIRCEP.110.959254</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21427276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, Maleszewski JJ, Edwards WD, Reeder G, Cooper LT, et al. 
Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis.
JACC Heart Fail. 2014;2:466–473. doi: 10.1016/j.jchf.2014.03.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4459501</ArticleId>
            <ArticleId IdType="pubmed">25194292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, Kaikkonen K, Tuohinen S, Haataja P, Kerola T, et al. 
Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.
Circulation. 2015;131:624–632. doi: 10.1161/CIRCULATIONAHA.114.011522</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25527698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen HS, Wang W, Wu SN, Liu JP.
Corticosteroids for viral myocarditis.
Cochrane Database Syst Revi. 2013;10:CD004471
doi: 10.1002/14651858.CD004471.pub3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24136037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peretto G, Sala S, Rizzo S, Palmisano A, Esposito A, De Cobelli F, Campochiaro C, De Luca G, Foppoli L, Dagna L, et al. 
Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation.
J Am Coll Cardiol. 2020;75:1046–1057. doi: 10.1016/j.jacc.2020.01.036</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32138965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito S, Toda K, Miyagawa S, Yoshikawa Y, Hata H, Yoshioka D, Domae K, Tsukamoto Y, Sakata Y, Sawa Y.
Diagnosis, medical treatment, and stepwise mechanical circulatory support for fulminat myocarditis.
J Artif Organs. 2018;21:172–179. doi: 10.1007/s10047-017-1011-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29236180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S, Xu S, Li C, Ran X, Cui G, He M, Miao K, Zhao C, Yan J, Hui R, et al. 
A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center study.
Sci China Life Sci. 2019;62:369–380. doi: 10.1007/s11427-018-9501-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30850929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pahuja M, Adegbala O, Mishra T, Akintoye E, Chehab O, Mony S, Singh M, Ando T, Abubaker H, Yassin A, et al. 
Trends in the incidence of in-hospital mortality, cardiogenic shock, and utilization of mechanical circulatory support devices in myocarditis (analysis of national inpatient sample data, 2005-2014).
J Card Fail. 2019;25:457–467. doi: 10.1016/j.cardfail.2019.04.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31035007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschöpe C, Van Linthout S, Klein O, Mairinger T, Krackhardt F, Potapov EV, Schmidt G, Burkhoff D, Pieske B, Spillmann F.
Mechanical unloading by fulminant myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA concepts.
J Cardiovasc Transl Res. 2019;12:116–123. doi: 10.1007/s12265-018-9820-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6497621</ArticleId>
            <ArticleId IdType="pubmed">30084076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annamalai SK, Esposito ML, Jorde L, Schreiber T, A Hall S, O’Neill WW, Kapur NK.
The impella microaxial flow catheter is safe and effective for treatment of myocarditis complicated by cardiogenic shock: an analysis from the global cVAD registry.
J Card Fail. 2018;24:706–710. doi: 10.1016/j.cardfail.2018.09.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30244180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang JJ, Lin MS, Chen TH, Chen DY, Chen SW, Hsu JT, Wang PC, Lin YS.
Heart failure and mortality of adult survivors from acute myocarditis requiring intensive care treatment - a nationwide cohort study.
Int J Med Sci. 2017;14:1241–1250. doi: 10.7150/ijms.20618</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5666557</ArticleId>
            <ArticleId IdType="pubmed">29104480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM, Avedissian L, Pearse LA, Potter RN, Tremaine L, et al. ; Department of Defense Cardiovascular Death Registry Group. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance.
J Am Coll Cardiol. 2011;58:1254–1261. doi: 10.1016/j.jacc.2011.01.049</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21903060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF.
Demographics and epidemiology of sudden deaths in young competitive athletes: from the United States National Registry.
Am J Med. 2016;129:1170–1177. doi: 10.1016/j.amjmed.2016.02.031</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27039955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J.
Sudden cardiac death caused by myocarditis in persons aged 1-49 years: a nationwide study of 14 294 deaths in Denmark.
Forensic Sci Res. 2019;4:247–256. doi: 10.1080/20961790.2019.1595352</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6713107</ArticleId>
            <ArticleId IdType="pubmed">31489390</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
